Dissecting the Genetic Variations Associated with Response to First-Line Chemotherapy in Patients with Small Cell Lung Cancer: A Retrospective Cohort Study

This retrospective cohort study examined genetic variations in 24 small cell lung cancer (SCLC) patients undergoing first-line chemotherapy, revealing that an increased epidermal growth factor receptor (EGFR) gene copy number may predict a positive chemotherapy response. Patients with partial response (PR) had a significantly longer median overall survival (14 months) compared to those with progressive disease (PD) (6.5 months). The study suggests EGFR amplification as a potential biomarker for selecting chemotherapy-responsive patients, though it notes limitations such as the small sample size and absence of a control group, indicating the need for further large-scale research.